Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Rizzetto

Showing results (161-170 of 198) with videos related to

Pageof 20
Sort By:
Hepatology (Baltimore, Md.)|September 26, 2002
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapyGiorgio Saracco, Alda Olivero, Alessia Ciancio, et al.
The New England Journal of Medicine|July 1, 2005
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis BStephanos J Hadziyannis, Nicolaos C Tassopoulos, E Jenny Heathcote, et al.
Gastroenterology|December 10, 2013
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis CMaria Buti, Kosh Agarwal, Yves Horsmans, et al.
European Journal of Gastroenterology & Hepatology|September 24, 2011
Safety of propofol in cirrhotic patients undergoing colonoscopy and endoscopic retrograde cholangiography: results of a prospective controlled studyEmanuela Fagà, Mariella De Cento, Chiara Giordanino, et al.
Hepatology (Baltimore, Md.)|June 19, 2012
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trialsPatrick Marcellin, Hugo Cheinquer, Manuela Curescu, et al.
Therapeutic Drug Monitoring|March 13, 2012
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatmentAntonio DʼAvolio, Alessia Ciancio, Marco Siccardi, et al.
Gastroenterology|November 8, 2006
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 yearsStephanos J Hadziyannis, Nicolaos C Tassopoulos, E Jenny Heathcote, et al.
Haematologica|December 7, 2007
Italian blood donors with anti-HBc and occult hepatitis B virus infectionPaola Manzini, Mauro Girotto, Raffaele Borsotti, et al.
World Journal of Gastroenterology|January 27, 2006
Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest ItalyGiorgio Palestro, Rinaldo Pellicano, Gian Ruggero Fronda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 21, 2013
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisionsAlessandra Mangia, Tivadar Bányai, Giuseppe De Bartolomeo, et al.
Pageof 20

Showing results (161-170 of 198) with videos related to

Sort By:
Pageof 20
Hepatology (Baltimore, Md.)|September 26, 2002
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapyGiorgio Saracco, Alda Olivero, Alessia Ciancio, et al.
The New England Journal of Medicine|July 1, 2005
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis BStephanos J Hadziyannis, Nicolaos C Tassopoulos, E Jenny Heathcote, et al.
Gastroenterology|December 10, 2013
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis CMaria Buti, Kosh Agarwal, Yves Horsmans, et al.
European Journal of Gastroenterology & Hepatology|September 24, 2011
Safety of propofol in cirrhotic patients undergoing colonoscopy and endoscopic retrograde cholangiography: results of a prospective controlled studyEmanuela Fagà, Mariella De Cento, Chiara Giordanino, et al.
Hepatology (Baltimore, Md.)|June 19, 2012
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trialsPatrick Marcellin, Hugo Cheinquer, Manuela Curescu, et al.
Therapeutic Drug Monitoring|March 13, 2012
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatmentAntonio DʼAvolio, Alessia Ciancio, Marco Siccardi, et al.
Gastroenterology|November 8, 2006
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 yearsStephanos J Hadziyannis, Nicolaos C Tassopoulos, E Jenny Heathcote, et al.
Haematologica|December 7, 2007
Italian blood donors with anti-HBc and occult hepatitis B virus infectionPaola Manzini, Mauro Girotto, Raffaele Borsotti, et al.
World Journal of Gastroenterology|January 27, 2006
Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest ItalyGiorgio Palestro, Rinaldo Pellicano, Gian Ruggero Fronda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 21, 2013
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisionsAlessandra Mangia, Tivadar Bányai, Giuseppe De Bartolomeo, et al.
Pageof 20